With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
August 11, 2017. He was a professional baseball pitcher who made it big with an unorthodox wind-up in the 90s....around the same time as the emergence of HPV+ oropharyngeal cancer (OPC). HPV really changed the OPC game, ushering in patients with stage IV disease outliving all odds (on the order of >70%). In other words, all our OPC prognostic data was sent to the dugout. Enter the new OPC prognostic nomogram presented in JCO this week. It’s based on data from two recent (negative) head and neck radiation trials: the RTOG 0129 and RTOG 0522....because they had to use all that data for something. It doesn’t offer a huge advantage over the RTOG 0129's secondary analysis risk flow chart (Figure 2A) we all know and love. But one big benefit is the integration of the PFS and OS nomograms into the NRG Oncology webpage that quickly spits out 2 and 5 year survivals, which may surprise you. Now how’s that for a Hideo Nomo-gram risk factor wind-up and estimated survival pitch.